Assessment of Serum Lipid Profile in Sudanese Diabetic Patients Treated with Insulin and/or Oral Hypoglycemic Medications

Abstract

Insulin resistance is the pathophysiological basis of dyslipidemia and hyperglycemia Most lipid abnormalities in type 2 diabetes can be explained by reduced action of insulin at the tissuelevel This cross sectional study was carried out to assess the impact of diabetes mellitus on lipid profile of Sudanesediabeticpatients treated with insulin andor oral hypoglycemic agentsat Kosti teaching hospital during October 2008 April 2009 One hundred and sixty three diabetic patients aged between 1585years were included They were informed and consented to participate in this study Subjected patients were classified into three groups according to their medication group A (n=36)includes patientstreated with insulin group B (n=113)were patients treated withhypoglycemic agents and group C (n=14) those whom wereusing combination of both insulin and oral hypoglycemic agent as treatment Patientsblood samples were taken and examined for lipids profile and HbA1C using spectrophotometric and chromatographic techniques respectively Obtained data were analyzed using SPSS program for windows V 20 Usingstudentt test Patients results were compared with results of one hundred persons as controls In this study there was an elevatedmean level ofcholesterol4.88±1.55mmol/L triglycerides(2.2±0.66mmol/L)LDL(3.1±1.76mmol/L) ApoB(1.48±0.6g/L)and HbA1C(10.4±4.5%) and reduced mean levels of HDL(1.15±0.36mmol/L)and ApoA (1.62±0.1g/L)in all groupswhen compared with control All patients were having HbA1C>9%.Mean values ofcholesterol triglycerides LDL HDL ApoB ApoA and HbA1C of diabetic patients were found non-significant when compared with controls (P values were 0.340 0.802 0.489 0.812 0.342 0.490 and 0.840) respectively The assessment of lipid profile in serum of diabetic patients treated with insulin and/or oral hypoglycemic agents should be done to reduce the risk of fat gain to diabetic patients Glycemic control and treatment of dyslipidemia reduces the development and progression of diabetic complications